

- 26 -

Claims

1. A therapeutic combination product for use in the prevention and/or treatment of asthma comprising (a) a medicament comprising a surface active phospholipid (SAPL) composition in finely divided form, the SAPL including a component which enhances spreading of the medicament over a surface at about normal mammalian body temperature and (b) an antiasthma drug, wherein ingredients (a) and (b) are provided in a form for administration together or separately.
2. A combination product as claimed in claim 1, in which the ingredient (a) consists of a first component comprising one or more phosphatidyl cholines and a second component comprising one or more compounds selected from the group consisting of phosphatidyl glycerols, phosphatidyl ethanolamines, phosphatidyl serines, phosphatidyl inositols and chlorestyl palmitate.
3. A combination product as claimed in claim 2, in which medicament (a) comprises said first component and said second component in a weight ratio of from 1:9 to 9:1.
4. A combination product as claimed in claim 3, in which the proportion by weight of said first component exceeds that of said second component.
5. A combination product as claimed in claim 4, in which said first component and said second component are present in a weight ratio of from 6:4 to 8:2.
6. A combination product as claimed in any one of claims 1 to 5, in which the medicament (a) comprises a phosphatidyl glycerol.
7. A combination product as claimed in claim 6, in which the phosphatidyl glycerol comprises one or more diacyl phosphatidyl glycerols, of which at least a proportion of the acyl groups are unsaturated.

09856400.091701

a

WO 00/30654

PCT/GB99/03952

Sub
a5

8. A combination product as claimed in any one of claims 1 to 7, in which the medicament (a) comprises one or more compounds selected from the group consisting of diacyl phosphatidyl choline.

5 9. A combination product as claimed in claim 8, in which the medicament (a) comprises dipalmitoyl phosphatidyl choline.

Sub
a6

10 10. A combination product as claimed in any one of claims 1 to 9, in which the medicament (a) in micronised form.

11. A combination product as claimed in any one of claims 2 to 10, in which said medicament (a) has a median particle size not exceeding 10µm.

15 12. A combination product as claimed in claim 11, in which said medicament (a) has a median particle size not exceeding 5µm.

13. A combination product as claimed in claim 12, in which said medicament (a) has a median particle size of less than 3µm.

20 14. A combination product as claimed in any one of claims 1 to 13, in which the antiasthma drug comprises one or more respiratory drugs selected from the group consisting of β_2 -agonists, steroids, cromones, antimuscarinic drugs and leukotriene receptor antagonists.

Sub
a7

25 15. A combination product as claimed in any one of claims 1 to 14, which comprises one or more said antiasthma drugs in an amount of up to 10 parts by weight per hundred parts by weight of said first and second components of medicament (a) in combination.

30 16. A delivery device as claimed in claim 15, which comprises one or more said respiratory drugs in an amount of up to one part by weight per hundred parts by weight of said

008556400-091704

- 28 -

first and second components of medicament (a) in combination.

17. A combination product as claimed in any one of claims 1 to 16, in which ingredient (b) comprises a β_2 -agonist.

18. A combination product as claimed in any one of claims 1 to 16, in which ingredient (b) comprises a steroid.

19. A combination product as claimed in any one of claims 1 to 16, in which ingredient (b) comprises a cromone.

20. A combination product as claimed in any one of claims 1 to 16, in which ingredient (b) comprises a leukotriene receptor antagonist.

21. A combination product as claimed in any one of claims 1 to 16, in which ingredient (b) comprises an antimuscarinic drug.

22. A combination product as claimed in any one of claims 1 to 21, in which at least ingredient (a) is arranged to be delivered to a patient in the form of at least one individual inhalable dose, the or each individual dose comprising said ingredient (a) in an amount of at least 10mg.

23. A combination product as claimed in claim 22, in which the or each individual dose comprises said first and second components in a combined amount of at least 25mg.

24. A combination product as claimed in claim 23, in which the or each dose comprises said ingredient (a) in a combined amount of at least 40mg.

25. A combination product as claimed in any one of claims 22 to 24, in which at least ingredient (a) is arranged for sequential delivery of a multiplicity of inhalable doses.

Ant
Sub
a7

0985400.091701

- 29 -

26. A combination product as claimed in any one of claims 1 to 25, in which the antiasthma drug is arranged for delivery in admixture with ingredient (a).

27. A combination product as claimed in any one of claims 1 to 26, in which the antiasthma drug is arranged for delivery separately from, and simultaneously or sequentially with, ingredient (a).

28. A pack for use as part of a combination product according to any one of claims 1 to 27, said pack including a delivery device for delivery of ingredient (a) to a patient and further comprising instructions to use said delivery device in a method of treatment including the separate simultaneous or sequential administration of an antiasthma drug.

29. A method of prevention and/or treatment of asthma, comprising administering to a patient at least one dose of a combination product as defined in any one of claims 1 to 27.

30. A delivery device for administering to a patient by inhalation a medicament for the prevention and/or treatment of asthma, the delivery device containing a medicament comprising a surface active phospholipid (SAPL) composition in finely divided form, the SAPL including a component which enhances the spreading of the medicament, the delivery device being arranged for delivery of at least one individual dose in an amount of at least 10mg.

31. A delivery device for administering to a patient by inhalation a medicament for the prevention or treatment of asthma, the delivery device containing a medicament comprising a first component consisting of one or more phosphatidyl cholines and a second component consisting of one or more compounds selected from the group consisting of phosphatidyl glycerols, phosphatidyl ethanolamines, phosphatidyl serines, phosphatidyl inositols and chlorestyl

Cont
sub
G7

0956400-091704

Sub
B3

- 30 -

palmitate, the delivery device being arranged for delivery of at least one individual inhalable dose, the or each individual dose comprising said first component and said second component in a combined amount of at least 10mg.

5 32. A delivery device as claimed in claim 30 or claim 31, in which the medicament is as defined in any one of claims 2 to 13.

33. A delivery device as claimed in any one of claims 30 to 32, which further includes means for dispensing an
10 inhalable dose of an antiasthma drug.

34. Use of (a) a surface active phospholipid (SAPL) composition in finely divided form conjointly with (b) an antiasthma drug in the manufacture of a medicament for the control of asthma.

15 35. A combination product for use in the prevention or treatment of asthma comprising

(a) a medicament comprising a first phospholipid component which is capable of binding to lung tissue and a second component which is capable of enhancing the spreading
20 of said first component over an aqueous medium at 37°C, said medicament being in the form of a finely divided powder; and

(b) an antiasthma drug;
the ingredients (a) and (b) being arranged for administration in combination or separately, simultaneously
25 or sequentially.

Sub
98

09856400.00495860

Sub
94

Add
05